Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

St James's Place rallies as JPMorgan reiterates 'strong conviction', lifts PT

(Sharecast News) - St James's Place jumped to the top of the FTSE 100 on Friday as JPMorgan Cazenove reiterated its 'strong conviction' on the overweight-rated stock and lifted the price target to 1,310p from 1,205p. "St James's Place remains a top conviction within our coverage universe," it said.

The bank said it was updating its St James's Place model, incorporating the reported Q1 assets under management, while also reflecting in its estimates the good market performance of recent weeks.

"As a result, we increase our 2025-27 underlying cash earnings per share estimates by 8-12%, primarily thanks to a circa 6% increase in our funds under management assumptions," it said.

"The higher FUM leads to a 4%-6% increase in net income, which is then amplified at the EPS level by operating margins as we make no changes to our cost estimates," said JPM, which lifted its price target accordingly.

It said that impressive strength in net flows over past 12 months demonstrate to the bank that St James's Place is well on track to continue to grow and capture market share in the UK wealth management market.

"Whilst the repricing, which will kick in over the summer, will lead to a sequential decline in EPS in 2025 and 2026, this is already reflected in consensus, and we expect that attention will gradually shift to the appealing long-term growth trajectory for the business (JPMe 25% EPS compound annual growth rate over 2026-30), and drive a gradual re-rating in the stock," JPM said.

At 1110 BST, the shares were up 4.8% at 1,122p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.